Ph.D., CEO, Bexion Pharmaceuticals
Biography
Ray Takigiku is the founder of Bexion Pharmaceuticals, an oncology-focused company with a novel compound in clinical development for solid tumors, including glioblastoma multiforme, a deadly form of brain cancer; and potential for other rare tumors. Ray is an entrepreneurial life scientist with over 30 years of experience in the discovery, development, and market support of innovative pharmaceuticals. At P&G Pharmaceuticals, Ray was on the leadership team behind the blockbuster Actonel. After leaving P&G, Ray joined SIDIS Global, an investment and management firm creating cutting edge bio-instrumentation and next generation medical devices.
Immunotherapy Showcase:
Bexion Pharmaceuticals
Bexion is clinical stage, oncology-focused company with an innovative pipeline-in-a-product asset.
Safety And Pharmacokinetics Of BXQ-350 In A Phase 1a And 1b Trial Of Solid Tumors And High-Grade Glioma
Bexion believes that combining current approaches with novel, innovative therapeutics will create new avenues of stopping disease progression and prolonging patient lives. Key to these innovative therapeutics will be strong safety profiles, and demonstrated tumor targeting properties.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 23 9.00 A.M.-10.45 A.M.
The PMWC 2020 Immunotherapy Showcase will provide a 15-minute time slot for selected immunotherapy companies to present their latest technologies and advancements to an audience of leading investors, potential clients, and partners. We will hear from companies building new cell-based immunotherapies, work in the growing area of cancer vaccines, that help understand the relevance of the tumor microenvironment, accelerate the patient selection process, or otherwise work towards overcoming to challenges related to therapeutic discovery.
